Skip To Content

Daraprim TPP Settlement

1-877-316-0144

This official website is maintained by the Claims Administrator for the lawsuit, BCBSM, Inc. v. Vyera Pharmaceuticals, et al., No. 21-cv-1884-DLC pending in the United States District Court for the Southern District of New York.
UPDATE:

On June 17, 2022, the Court granted final approval to the Settlement and entered Final Judgment. The Corporate Defendants made their first guaranteed payment of $7 million into the Class Settlement Fund on February 22, 2022. The Corporate Defendants have made four additional, contingent payments into the Class Settlement Fund between May 2, 2022 and April 12, 2023, totaling roughly $1,726,363.96. Lead Counsel is evaluating the likelihood and potential timing of any additional contingent settlement payments to determine when distributing the Class Settlement Funds will be most cost-effective. Lead Counsel will move the Court to authorize distribution of the Class Settlement Funds at the soonest cost-effective time, pursuant to the Plan of Allocation and Final Judgment.

Court Documents

Final Judgment And Order Of Dismissal Order Re Fees And Expenses Order Rescheduling Time of Fairness Hearing Order Granting Plaintiff’s Motion for Preliminary Approval Final Order Against Shkreli In Government Action Opinion And Order Against Shkreli In The Government Action Stipulated Order In Government Action Settlement Agreement Amended Class Action Complaint

Note: These documents are in PDF format. To view the
documents, you will need Adobe Acrobat Reader on your computer or other internet-enabled device.

Adobe Acrobat Reader